3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial

Iveson TJ., Kerr RS., Saunders MP., Cassidy J., Hollander NH., Tabernero J., Haydon A., Glimelius B., Harkin A., Allan K., McQueen J., Scudder C., Boyd KA., Briggs A., Waterston A., Medley L., Wilson C., Ellis R., Essapen S., Dhadda AS., Harrison M., Falk S., Raouf S., Rees C., Olesen RK., Propper D., Bridgewater J., Azzabi A., Farrugia D., Webb A., Cunningham D., Hickish T., Weaver A., Gollins S., Wasan HS., Paul J.

DOI

10.1016/s1470-2045(18)30093-7

Type

Journal article

Journal

The Lancet Oncology

Publisher

Elsevier BV

Publication Date

04/2018

Volume

19

Pages

562 - 578

Permalink Original publication